By DEEKSHA HEGDE
I had an itch to attract parallels between the 2. The structural info stored lining up in methods I couldn’t dismiss, and by the tip, I finished attempting.
Perform’s product is an app: you pay $365 a yr, go to a Quest Diagnostics location, get 160+ biomarkers examined twice a yr, and obtain clinician-written notes decoding your outcomes. The lab testing is absolutely outsourced. Perform is the layer on high: panel design, member expertise, clinician be aware era, longitudinal monitoring.
Perform Well being raised $298 million at a $2.5 billion valuation in November 2025. At 25x income, the market clearly isn’t shopping for a lab reseller. It’s shopping for the info flywheel: longitudinal biomarker histories that compound in scientific worth over time, aggregated throughout lots of of hundreds of members right into a dataset that well being plans, pharma firms, and AI builders can’t construct another approach. A member with 4 years of knowledge can’t swap to a less expensive competitor with out dropping the pattern. The unit economics work if the interpretation layer scales with out proportionally scaling headcount, which is what the Medical Intelligence Lab, their generative AI mannequin launched in November 2025, is constructed to do. Perform can also be constructing towards a B2B enterprise channel, positioning the product as a method to maintain staff “wholesome, targeted, and able to carry out.”
It satisfies a burning want for particular personas: the anxious nicely, the well being optimizers, the individuals who noticed their family members get recognized a bit of too late, the individuals who aren’t ready for a analysis earlier than they begin paying consideration. These are folks the remainder of the trade has largely left alone. I wrote earlier this yr, in a chunk on Hinge Well beingin regards to the prevention paradox: the employer ROI mannequin is structurally blind to the member who advantages most from early intervention. Perform skips the employer ROI story fully, fees the member straight, and doesn’t attempt to show a CFO case it may’t make. But.
Take apoB, brief for apolipoprotein B, one in all Perform’s most prominently marketed biomarkers, a greater predictor of cardiovascular threat than the LDL take a look at most annual physicals nonetheless depend on. The Swedish AMORIS cohort examine adopted 137,000 folks for a mean of 17.8 years and located that elevated apoB separates instances from controls roughly 20 years earlier than a serious cardiovascular occasion, with the hole sharpening over the last decade closest to the occasion. Catch it, act on it — statins, dietary adjustments, nearer monitoring — and you might stop a coronary heart assault. That’s actual scientific worth.
Now run the employer math. Median personal sector tenure in america is 3.5 years. The employer funding the Perform membership will virtually definitely not be insuring this individual when that cardiovascular occasion materializes. The prevented value accrues to whoever covers them in fifteen years. The CFO writing the test right this moment captures none of it. What Perform is definitely promoting proper now to employers is a wellness perk. Higginbotham, an insurance coverage dealer, introduced a partnership in January 2026 providing Perform to staff at $334 as an alternative of $365. A $31 low cost. You don’t construct a $2.5 billion firm on a gymnasium stipend.
What well being plans and pharma companions would really pay for doesn’t exist but: actuarial threat fashions and analysis datasets constructed on years of longitudinal biomarker knowledge at scale. The D2C subscription is the info acquisition engine for that product. Every thing will depend on the flywheel operating lengthy sufficient to shut the hole.
That’s the place the 23andMe comparability clicked for me.
23andMe was a D2C well being knowledge firm whose valuation rested on a knowledge monetization thesis: pharma analysis partnerships, knowledge licensing. Equipment gross sales alone couldn’t justify it. It wasn’t a HIPAA-covered entity, and it collected delicate well being knowledge underneath a privateness coverage that reserved the best to switch it in a sale or chapter. The patron advertising and marketing, although, by no means mentioned any of this. 23andMe led with ancestry, which made it viral, emotionally sticky, and FDA-adjacent fairly than FDA-regulated. Well being studies had been the upsell. “Contributing to science” was how they framed knowledge acquisition: altruism, not a transaction. The GSK partnership ($300 million for analysis entry to the genetic database) was disclosed within the phrases of service, for the individuals who learn the wonderful print. When the enterprise failed, the info was a sellable asset, and Regeneron grabbed it in a storage sale.
Perform is structurally comparable, with larger stakes on each dimension. D2C well being knowledge firm, knowledge monetization thesis: enterprise threat fashions, analysis partnerships, AI. Additionally not a HIPAA-covered entity. It doesn’t invoice insurance coverage and isn’t a lined healthcare supplier, which suggests the authorized protections most members assume apply to their well being knowledge don’t. The identical chapter switch loophole that caught 23andMe’s members would catch Perform’s too.
23andMe’s income mannequin was damaged from day one: purchase a equipment as soon as, achieved. Perform has recurring subscriptions and actual switching prices. 23andMe additionally imploded attempting to develop into a therapeutics firm, a pivot that required capabilities fully overseas to what it had. Perform’s monetization path is no less than adjoining to what it already does.
However the regulatory publicity is similar, and that window is closing. The FTC up to date its Well being Breach Notification Rule in April 2024, explicitly extending it to well being apps and D2C platforms, and has already used it towards GoodRx, Premom, and BetterHelp. HYPERthe Well being Info Privateness Reform Act launched in November 2025, would prolong HIPAA-equivalent obligations to precisely the class of firm Perform is.
The info Perform holds makes this publicity worse. 23andMe held genetic predisposition knowledge: probabilistic, future-oriented, a threat modifier. Perform’s biomarker knowledge is present: thyroid perform, metabolic standing, hormonal profile, cardiovascular markers, up to date twice a yr. Extra actionable, extra temporally exact, extra straight helpful to anybody making selections based mostly in your well being.
Which ends up in an issue Perform hasn’t absolutely named. Their D2C model runs on a selected promise: your knowledge is yours, and we’re serving to you perceive it. That’s what acquired 200,000 members. 23andMe acquired its first tens of millions the identical approach, utilizing aspirational identification advertising and marketing to seize knowledge property, whereas the precise worth creation required a B2B transaction that the patron advertising and marketing by no means ready the consumer for. Perform’s member base skews extra refined than 23andMe’s ever did — these are individuals who already imagine their knowledge has scientific worth. Perform’s advertising and marketing hasn’t constructed the narrative structure but to ask them right into a transaction they’re already in.
The playbook exists. Oura selected the NBA and UCSF as analysis companions. These are establishments that made members really feel like individuals in one thing elite and scientific. Whoop publishes findings utilizing mixture member knowledge. In each instances, the identical underlying knowledge transaction reads as an identity-enhancing contribution as a result of the framing was constructed into the model from the beginning, not buried within the phrases of service. Perform’s biomarker knowledge is extra clinically delicate than wearable knowledge like HRV and sleep phases, and its B2B thesis extra load-bearing, which suggests the identical playbook wants extra rigor in execution. Associate choice is model work: the primary disclosed analysis partnerships will set the body for every little thing. Publishing findings normalizes the info relationship whereas constructing the product validity case Perform wants earlier than well being plans will write a test.
Perform is already executing on components of this playbook — the NBPA partnership in February 2026 brings biomarker testing to skilled athletes, and the model sign is actual. However a distribution deal isn’t a analysis relationship. What’s lacking is analysis partnerships structured to provide and publish findings, the type that flip distribution into proof, and proof into retention.
There’s one other layer that neither Oura nor Whoop has constructed. Proactive knowledge governance is what makes the contribution framing credible fairly than simply model copy. Perform at present describes itself as “HIPAA-aligned”, following key necessities of the Safety Rule voluntarily. That’s the hole in a single phrase. Safety practices with out authorized dedication don’t shut the chapter switch loophole, don’t fulfill IRB consent necessities for future pharma companions, and don’t give insurance coverage companions the reassurance they should license a dataset with out importing regulatory publicity. Adopting HIPAA-equivalent knowledge dealing with earlier than HIPRA passes and framing it as a product resolution fairly than a compliance response protects the flywheel from being dismantled earlier than it matures.
Perform has a window to behave by itself phrases. 23andMe waited for regulators to put in writing the principles and have become the cautionary story these guidelines had been named after. Perform may write the playbook as an alternative.
Deeksha Hegde is a bioengineer who writes about healthtech and digital well being positioning on Substack.
